ES3005508T3 - Compositions and methods for beta secretase inhibition - Google Patents

Compositions and methods for beta secretase inhibition Download PDF

Info

Publication number
ES3005508T3
ES3005508T3 ES18816475T ES18816475T ES3005508T3 ES 3005508 T3 ES3005508 T3 ES 3005508T3 ES 18816475 T ES18816475 T ES 18816475T ES 18816475 T ES18816475 T ES 18816475T ES 3005508 T3 ES3005508 T3 ES 3005508T3
Authority
ES
Spain
Prior art keywords
less
baicalein
chrysin
oroxylin
secretase
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES18816475T
Other languages
English (en)
Spanish (es)
Inventor
Muhammed Majeed
Kalyanam Nagabhushanam
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sami Chemicals and Extracts Ltd
Original Assignee
Sami Chemicals and Extracts Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sami Chemicals and Extracts Ltd filed Critical Sami Chemicals and Extracts Ltd
Application granted granted Critical
Publication of ES3005508T3 publication Critical patent/ES3005508T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Mycology (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Confectionery (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ES18816475T 2017-06-15 2018-06-14 Compositions and methods for beta secretase inhibition Active ES3005508T3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762520141P 2017-06-15 2017-06-15
PCT/US2018/037454 WO2018232063A1 (en) 2017-06-15 2018-06-14 Compositions and methods for beta secretase inhibition

Publications (1)

Publication Number Publication Date
ES3005508T3 true ES3005508T3 (en) 2025-03-14

Family

ID=64655980

Family Applications (1)

Application Number Title Priority Date Filing Date
ES18816475T Active ES3005508T3 (en) 2017-06-15 2018-06-14 Compositions and methods for beta secretase inhibition

Country Status (9)

Country Link
US (2) US11458117B2 (cg-RX-API-DMAC10.html)
EP (2) EP3638277B1 (cg-RX-API-DMAC10.html)
JP (2) JP7209645B2 (cg-RX-API-DMAC10.html)
KR (2) KR20190134809A (cg-RX-API-DMAC10.html)
CA (2) CA3063751C (cg-RX-API-DMAC10.html)
ES (1) ES3005508T3 (cg-RX-API-DMAC10.html)
FI (1) FI3638277T3 (cg-RX-API-DMAC10.html)
PL (2) PL3638277T3 (cg-RX-API-DMAC10.html)
WO (2) WO2018232063A1 (cg-RX-API-DMAC10.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3638277T3 (pl) * 2017-06-15 2025-03-10 Sami Labs Limited Kompozycje i sposoby hamowania beta sekretazy
US12465585B2 (en) * 2018-06-15 2025-11-11 Sami-Sabinsa Group Limited Compositions for the management of seizure induced neurotoxicity
CN110115712A (zh) * 2019-07-04 2019-08-13 兰州大学 一种同时激活氧化磷酸化通路和抑制糖酵解途径的激活剂及其应用
EP4021397A4 (en) * 2019-08-26 2023-09-27 Sami-Sabinsa Group Limited HERBAL ACTIVE INGREDIENTS AND THEIR EFFECT AGAINST POLLUTION
CN114246879B (zh) * 2021-12-30 2023-10-27 沈阳兴齐眼药股份有限公司 木蝴蝶苷b在制备用于预防、控制和/或治疗眼部疾病药物中的用途

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8945518B2 (en) * 2002-04-30 2015-02-03 Unigen, Inc. Formulation of dual eicosanoid system and cytokine system inhibitors for use in the prevention and treatment of oral diseases and conditions
CA2703698C (en) * 2002-04-30 2016-11-22 Unigen Pharmaceuticals, Inc. Formulation of a mixture of free-b-ring flavonoids and flavans as a therapeutic agent
US8034387B2 (en) * 2002-04-30 2011-10-11 Unigen, Inc. Formulation of a mixture of free-B-ring flavonoids and flavans for use in the prevention and treatment of cognitive decline and age-related memory impairments
NZ545565A (en) * 2003-09-02 2009-06-26 Unigen Pharmaceuticals Inc Formulation of a mixture of Free-B-Ring flavonoids and flavans for use in the prevention and treatment of cognitive decline and age-related memory impairments
KR20080091436A (ko) * 2006-01-09 2008-10-13 카운실 오브 사이언티픽 엔드 인더스트리얼 리서치 위장관 독성, 관련 증상 및 궤양 치료용 천연물질
EP1986670B1 (en) * 2006-02-21 2017-06-28 Council of Scientific and Industrial Research Intestinal alpha-glucosidase inhibitors and a process for the isolation and use thereof
US20100029654A1 (en) * 2006-03-23 2010-02-04 Mount Sinai School Of Medicine Cardiovascular compositions and use of the same for the treatment of alzheimer's disease
KR20080008929A (ko) * 2006-11-20 2008-01-24 대한민국(관리부서 식품의약품 안전청장) 오록실린 ａ를 함유하는 인지 기능 장애 관련 질환의 예방및 개선용 건강기능식품
EP2890391A4 (en) * 2012-08-29 2016-03-09 Mannkind Corp METHOD AND COMPOSITION FOR TREATING HYPERGLYCEMIA
CA3043168C (en) * 2016-11-11 2021-05-18 Sami Labs Limited Composition containing oroxylin a and method of extraction thereof
PL3638277T3 (pl) * 2017-06-15 2025-03-10 Sami Labs Limited Kompozycje i sposoby hamowania beta sekretazy

Also Published As

Publication number Publication date
JP7209645B2 (ja) 2023-01-20
US20180360800A1 (en) 2018-12-20
JP2020523372A (ja) 2020-08-06
EP3638277A4 (en) 2021-03-17
CA3063757A1 (en) 2018-12-20
JP6796217B2 (ja) 2020-12-02
US11458117B2 (en) 2022-10-04
US10894029B2 (en) 2021-01-19
CA3063751A1 (en) 2018-12-20
EP3638277B1 (en) 2024-10-09
CA3063751C (en) 2023-01-03
PL3638278T3 (pl) 2022-10-03
EP3638278A4 (en) 2021-03-17
KR20190131589A (ko) 2019-11-26
WO2018232063A1 (en) 2018-12-20
PL3638277T3 (pl) 2025-03-10
US20180360801A1 (en) 2018-12-20
EP3638278B1 (en) 2022-05-11
FI3638277T3 (fi) 2025-01-10
KR20190134809A (ko) 2019-12-04
EP3638277A1 (en) 2020-04-22
WO2018232224A1 (en) 2018-12-20
EP3638278A1 (en) 2020-04-22
JP2020523342A (ja) 2020-08-06
CA3063757C (en) 2023-08-01

Similar Documents

Publication Publication Date Title
Athar et al. Recent advances on drug development and emerging therapeutic agents for Alzheimer’s disease
Fujikake et al. Association between autophagy and neurodegenerative diseases
Marcelli et al. The involvement of post-translational modifications in Alzheimer's disease
Silva et al. Mitochondrial metabolism power SIRT2-dependent deficient traffic causing Alzheimer’s-disease related pathology
Corpas et al. SIRT1 overexpression in mouse hippocampus induces cognitive enhancement through proteostatic and neurotrophic mechanisms
Ly et al. Inhibition of GSK3β-mediated BACE1 expression reduces Alzheimer-associated phenotypes
Xuan et al. Valproic acid alleviates memory deficits and attenuates amyloid-β deposition in transgenic mouse model of Alzheimer’s disease
Meraz‐Ríos et al. Tau oligomers and aggregation in Alzheimer’s disease
Bai et al. Attenuation of Pb-induced Aβ generation and autophagic dysfunction via activation of SIRT1: Neuroprotective properties of resveratrol
Bhounsule et al. Cyclin dependent kinase 5: A novel avenue for Alzheimer’s disease
US11458117B2 (en) Compositions and methods for beta secretase inhibition
Zhang et al. Pseudoginsenoside-F11 alleviates cognitive deficits and Alzheimer’s disease-type pathologies in SAMP8 mice
Gatti et al. Oxidative stress in Alzheimer’s disease: in vitro therapeutic effect of amniotic fluid stem cells extracellular vesicles
Kowalska et al. Genetic variants and oxidative stress in Alzheimer’s disease
Lasure et al. Quercetin ameliorates neuroinflammatory and neurodegenerative biomarkers in the brain and improves neurobehavioral parameters in a repeated intranasal amyloid-beta exposed model of Alzheimer's disease
Motyl et al. Alpha-synuclein alters differently gene expression of Sirts, PARPs and other stress response proteins: implications for neurodegenerative disorders
Ge et al. TP53-induced glycolysis and apoptosis regulator (TIGAR) ameliorates lysosomal damage in the 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine-mediated mouse model of Parkinson’s disease
Yoon et al. Rosiglitazone reduces tau phosphorylation via JNK inhibition in the hippocampus of rats with type 2 diabetes and tau transfected SH-SY5Y cells
EP3193869A1 (en) Perk activator for the treatment of neurodegenerative diseases
Ahmed et al. Amplifying the heat shock response ameliorates ALS and FTD pathology in mouse and human models
Pasinetti et al. Development of a grape seed polyphenolic extract with anti‐oligomeric activity as a novel treatment in progressive supranuclear palsy and other tauopathies
Khairallah Alzheimer's disease: current status of etiopathogenesis and therapeutic strategies
Grimm et al. The impact of capsaicinoids on APP processing in Alzheimer’s disease in SH-SY5Y cells
Van Leeuwen et al. Frameshift proteins in Alzheimer's disease and in other conformational disorders: time for the ubiquitin-proteasome system
Du et al. Activation of TRPV4 induces intraneuronal tau hyperphosphorylation via cholesterol accumulation